Overview

Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Britannia Pharmaceuticals Ltd.
Treatments:
Apomorphine